Patents Examined by Gyan Chandra
  • Patent number: 10772935
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 15, 2020
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Patent number: 10765737
    Abstract: The present disclosure relates to methods for treating or preventing heart failure using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing heart failure (e.g., post-myocardial infarction heart failure), diabetic cardiomyopathy heart failure), and lateral ventricular (LV) remodeling, using antigen binding and antagonizing proteins, e.g., fully human antibodies, that specifically bind to and antagonize the function of the human glucagon receptor.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: September 8, 2020
    Assignee: REMD Biotherapeutics, Inc
    Inventor: Hai Yan
  • Patent number: 10751392
    Abstract: Provided are a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia provided in the present invention is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states, and therefore, the composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: August 25, 2020
    Assignee: IMMUNOFORGE CO., LTD.
    Inventors: Hee Sook Jun, Eun Young Park, Yeon Hee Hong
  • Patent number: 10752693
    Abstract: The present disclosure relates to methods for treating or preventing obesity and/or nonalcoholic fatty liver diseases (NAFLDs) and/or nonalcoholic steatohepatitis (NASH) using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing NAFLD/NASH using antigen binding and antagonizing proteins, e.g., fully human antibodies, that specifically bind to and antagonize the function of the human glucagon receptor.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: August 25, 2020
    Assignee: REMD Biotherapeutics, Inc.
    Inventors: Hai Yan, Jim Shi, Jeong Oh
  • Patent number: 10744282
    Abstract: One embodiment describes an insulin formulation that is specifically adapted for aerosolization. The formulation comprises a major amount of water and a minor amount of insulin. Further, the formulation is preservative free, without meta-cresol, cresol or phenol, to permit the formulation to be aerosolized using a vibrating aperture plate without substantial foaming of the insulin formulation.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: August 18, 2020
    Assignee: Aerami Therapeutics, Inc.
    Inventors: John S. Patton, Ryan S. Patton, Mei-chang Kuo, Yehuda Ivri
  • Patent number: 10744187
    Abstract: An insulin conjugate having improved in vivo duration and stability is provided. The conjugate is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 18, 2020
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Hae Song, Jae Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
  • Patent number: 10730999
    Abstract: The present invention generally relates to macromolecules of dendrimer-drug conjugates. In particular, the invention relates to macromolecules comprising a pharmaceutically active agent, such as a protein or peptide, attached to a core of a dendrimer derived from branched building units, such as lysine or lysine analogues. The invention also relates to the synthesis of the dendrimers and macromolecules, and the use of such macromolecules, particularly in therapeutic applications, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 4, 2020
    Assignee: Starpharma Pty Ltd
    Inventors: David James Owen, Pauline Stanislawski, Michael Giannis, Oliver Bernhard
  • Patent number: 10730923
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: August 4, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, David L. Smiley
  • Patent number: 10709766
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 14, 2020
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Patent number: 10711067
    Abstract: The present disclosure relates, in general, to methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: July 14, 2020
    Assignee: XOMA (US) LLC
    Inventors: Kirk W. Johnson, Rajneesh Nath, Paul Rubin
  • Patent number: 10696740
    Abstract: A method of treating a complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof, in a subject in need thereof, the method comprising of administering to the subject a therapeutically effective amount of an antibody which inhibits the alternative complement pathway, wherein the antibody administered is effective for inhibiting complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: June 30, 2020
    Assignee: NOVELMED THERAPEUTICS, INC.
    Inventor: Rekha Bansal
  • Patent number: 10696726
    Abstract: Disclosed herein are insulin agonist peptides conjugated to a glucagon analog wherein the insulin/glucagon conjugate is targeted to liver tissues upon administration to a patient.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 30, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Todd Parody, Jie Han, Pengyun Li
  • Patent number: 10688155
    Abstract: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: June 23, 2020
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Patent number: 10689427
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: June 23, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Patent number: 10676517
    Abstract: Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonists peptides.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 9, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Maria Aleksandra Bednarek, Lutz Ulrich Jermutus, Philip Ambery, Marcella Petrone
  • Patent number: 10660939
    Abstract: The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 26, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, John H. Dodd, Marie Makhlina
  • Patent number: 10639272
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: May 5, 2020
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 10626179
    Abstract: The present disclosure relates to methods for treating type 1 diabetes (T1D) using a glucagon receptor blocking agent. More specifically, the present disclosure relates to methods for treating T1D using substantially lower doses of insulin supplementation, or even in the absence of insulin supplementation, using antigen binding and antagonizing proteins, e.g., fully human antibodies that specifically bind to and antagonize the function of the human glucagon receptor.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: April 21, 2020
    Assignee: REMD Biotherapeutics, Inc.
    Inventors: Hai Yan, Jim Shi
  • Patent number: 10610504
    Abstract: The present invention relates to methods of generating a population of beta cells from a population of alpha cells, by contacting said population of alpha cells with GABA or a GABA receptor agonist, in combination with a monoclonal glucagon neutralizing antibody or other alpha cell mass regulating compounds, for an improved diabetes therapy.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 7, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NICE SOPHIA ANTIPOLIS-GRAND CHÂTEAU
    Inventors: Jacob Hecksher-Sørensen, Patrick Collombat
  • Patent number: 10596231
    Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: March 24, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen